|  |
| --- |
| **Supplementary e-Table 1.** Search strategy |
| **PubMed** | (“Amyloid”[Mesh] AND “positron emission tomography”[Mesh] OR “PET” OR “PET imaging” OR “amyloid imaging”) AND ("florbetapir" [Supplementary Concept] OR florbeta\*[tw] OR "flutemetamol"[tw]) OR (“Pittsburgh compound B” OR “PiB” OR “PIB” OR “11C Pittsburgh” or “PiB-PET” or “11C PiB-PET” OR “[11C]PiB") AND ("clinical setting" OR "clinical settings" OR "clinic\*” OR "memory clinic" OR "memory clinics" OR "clinical application" OR "clinical applications") AND (“utility”[tw] OR “routine”[tw] OR “diagnosis”[Mesh] OR “diagnostic”[tw]) |
| **Embase** | 'amyloid':ti AND ('positron emission tomography':ti OR 'pet':ti OR 'pet imaging':ti OR 'imaging':ti) AND ('florbetapir':ti,ab,de OR 'flutemetamol':ti,ab,de OR 'florbetaben':ti,ab,de OR 'pib':ti,ab,de OR 'pittsburgh compound b':ti,ab,de OR '11c pittsburgh':ti,ab,de OR 'pib-pet':ti,ab,de OR '11c pib-pet':ti,ab,de OR '[11c]pib':ti,ab,de) AND ('clinical setting':ti,ab,de OR 'clinical settings':ti,ab,de OR 'clinic\*':ti,ab,de OR 'memory clinic':ti,ab,de OR 'memory clinics':ti,ab,de OR 'clinical application':ti,ab,de OR 'clinical applications':ti,ab,de) AND ('utility':ti,ab,de OR 'routine':ti,ab,de OR 'diagnosis':ti,ab,de OR 'diagnostic':ti,ab,de) AND [2012-2018]/py |
| **Scopus** | ( TITLE ( "Amyloid" AND "positron emission tomography" OR "PET" OR "PET imaging" OR "amyloid imaging" ) AND TITLE-ABS-KEY ( "florbetapir" OR florbeta\* OR "flutemetamol" OR "Pittsburgh compound B" OR "PiB" OR "PIB" OR "11C Pittsburgh" OR "PiB-PET" OR "11C PiB-PET" OR "[11C]PiB" ) AND TITLE-ABS-KEY ( "clinical setting" OR "clinical settings" OR "clinic\*" OR "memory clinic" OR "memory clinics" OR "clinical application" OR "clinical applications" OR "utility" OR "routine" OR "diagnosis" OR "diagnostic" OR "multicenter" ) ) AND DOCTYPE ( ar ) AND PUBYEAR > 2011 |

**Supplementary e-Table 2. Risk of bias assessment**

|  |  |  |
| --- | --- | --- |
| Study | Sponsorship bias | Selection bias |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Funding Source** | **Possibility of sponsorship bias** | **Patients recruited** | **Possibility of selection bias** |
| Apostolova 2016 | 1) National Institute of Health 2) Easton Consortium for Alzheimer’s Drug Discovery and Biomarker Development. | N | All comers | N |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bensaidane 2016 | Nothing to disclose | N | Referred patients with uncertain diagnosis | Y |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Boccadi 2016 | 1) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) 2) Centro San Giovanni di Dio Fatebenefratelli 3) Avid Radiopharmaceuticals, Inc.\* (funding, provision of [18F]-florbetapir)\*Avid  | Y | Consecutive patients with cognitive impairment | N |
| Brendel 2017 | 1) Piramal Imaging provided florbetaben precursor2) Partial financial support rested on philanthropic donations to the Department of Neurology (Adrian Danek). | Y | Selected patients with MCI or dementia | Y |
| Carswell 2017 | No specific external funding was acquired.  | U | All comers | N |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceccaldi 2017 | Funded by Piramal Imaging | Y | Selected patients with most complex or atypical clinical situations  | Y |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Frederiksen 2012 | Nothing to disclose | N | Referred patients with uncertain etiology | Y |
| Grundman 2013 | Avid Radiopharmaceuticals. | Y | Selected patients with a history of cognitive decline or uncertain diagnosis | Y |
| Mitsis 2014 | Icahn School of Medicine Alzheimer’s Disease Research Center grant (P50 AG05138.) | N | All comers | N |
| Ossenkoppele 2013 | Performed within the framework of CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project LeARN (Grant 02N-101). | N | All comers | N |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pontecorvo 2017 | Registered clinical trial; Some authors are employee of or affiliated with Avid, Eli Lilly, etc. | Y | Selected patients with evidence of MCI or dementia;  | Y |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sanchez-Juan 2014 | 1) Institute for Formation and Research of the Foundation “Marqués de Valdecilla,” Instituto de Salud Carlos III; European Union Joint Programme—Neurodegenerative Disease Research; 2) United States NIH 3) State of California Department of Health Services Alzheimer’s Disease Research Center of California grant4) Alzheimer’s Association grant5) John Douglas French Alzheimer’s Foundation6) Hellman Family Foundation7) Tau ConsortiumSome authors are affiliated with Eli Lilly, GE, etc.  | Y | All comers who had undergone amyloid PET assessment | N |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Schipke 2012 | Not provided | U | Selected patients with probable AD or healthy controls; questionnaire study  | Y |
| Weston 2016 | 1) Wolfson Foundation2) NIHR Queen Square Dementia BRU, UCL/H Biomedical Research Centre3) UCL ECMC4) Alzheimer’s Research UK \*AVID Radiopharmaceuticals provided florbetapir ligand  | Y | All comers with previous assessment with CSF | Y |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Zwan 2017 | 1) Dutch Alzheimer’s Society 2) Unrestricted grant of GE Healthcare to the Stichting Alzheimer & Neuropsychiatrie, Amsterdam.  | Y | Patients with mild or early-onset dementia | Y |

|  |
| --- |
| Y = yes, N = no, U = unclear |